semaglutide drug company A big win for Wegovy: Weight loss first in history to gain FDA approval for reducing heart risks FDA Warns on Certain Forms

Clinical trials show average weight reductions of 1520% of body weight with consistent treatment and lifestyle changes

Make protein a priority at every meal , aiming for 20 to 30 grams

Front endocrinology

Retatrutide: Designed to Last One of the newest GLP-1 medications in development is retatrutide , a triple agonist (GLP-1, GIP, and glucagon receptors) designed with an approximate 6-day half-life , thanks to advanced pharmaceutical engineering

It is recommended to limit your intake of alcohol while on this medication

Outcome measures The percentage change from baseline in body weight was assessed once every three months and at the end of the follow-up period from treatment initiation